MNPR
Monopar Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$400.40M
P/E Ratio
—
EPS
$-1.93
Beta
1.54
52W High
$105.00
52W Low
$29.18
50-Day MA
$58.50
200-Day MA
$66.01
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to developing proprietary therapies to improve clinical outcomes for cancer patients in the United States. The company is headquartered in Wilmette, Illinois.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -15.90% |
| Return on Assets | -12.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $20.59 |
| Price-to-Book | 2.92 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -2.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $6.70M |
| Float | $4.13M |
| % Insiders | 23.23% |
| % Institutions | 93.28% |
Historical Volatility
HV 10-Day
29.88%
HV 20-Day
69.71%
HV 30-Day
71.17%
HV 60-Day
61.35%
HV Rank
47.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($112.62 target)
4
Strong Buy9
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026